Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab consolidation after concurrent chemoradiotherapy in pathologically residual esophageal squamous cell carcinoma
ChiCTR2200063345Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2200063345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063345.